loading...
Giving your business a clear and simple path to funding.
Notice of Intent to Issue Fiscal Year 2025 Solar Module and Solar Hardware (SMASH) Incubator Notice of Funding Opportunity The Office of Energy Efficiency and Renewable Energy (EERE) intends to issue, on behalf of the Solar Energy Technologies Office (SETO), a Notice of Funding Opportunity (NOFO) entitled “Fiscal Year 2025 Solar Module and Solar Hardware (SMASH) Incubator Notice of Funding Opportunity.” This NOFO seeks to address the lack of sufficient private investment that is available to successfully commercialize research and development (R&D) and research, development, and demonstration (RD&D) activities and bring innovative solar photovoltaic (PV) technology to market. Prime recipients of awards funded through this NOFO will be for-profit entities, with institutions of higher education, for-profit entities, nonprofit entities, state and local governmental entities, and federally recognized Indian Tribes as eligible subrecipients to provide technical expertise, technology know-how, and technical validation capabilities. Successful applications to this NOFO will be selected from three topic areas: 1. Crystalline silicon (c-Si) module technology, covering all segments of the c-Si PV module supply chain from input materials and production equipment through module assembly. 2. Cadmium telluride (CdTe) module technology, covering all segments of the CdTe PV module supply chain, including improvements in materials, processes, manufacturing, components, metrology, demonstration, recycling, and reclamation. 3. Non-module hardware technology, including structural and electrical components and tools that improve performance, functionality, reliability, or ease of installation for PV systems.
| NOAA Ocean Exploration is soliciting proposals for ocean exploration-related projects under two themes: Ocean Exploration and Maritime Heritage. By supporting exploration (i.e., examining unknown or poorly understood areas of the seafloor, sub-bottom, or water column through initial assessments of the physical, chemical, geological, biological, archaeological, or other characteristics), NOAA Ocean Exploration seeks to advance our basic understanding of the unknown ocean. All proposed projects must support priorities in the NOAA Ocean Exploration Strategic Plan (https://oceanexplorer.noaa.gov/about/what-we-do/media/noaa-oe-strategic-plan_fy23-fy27.pdf) and should also consider the Strategic Priorities for Ocean Exploration and Characterization of the United States Exclusive Economic Zone (https://www.whitehouse.gov/wp-content/uploads/2022/10/NOMEC_OEC_Priorities_Report.pdf). Proposed projects are not restricted to waters under U.S. jurisdiction, but proposals should address how projects will provide national benefit.For Fiscal Year 2025 (FY25) funding, NOAA Ocean Exploration is soliciting proposals focused on one of the following two themes:OCEAN EXPLORATION: Ocean Exploration proposals should support exploration of unknown or poorly known ocean areas, processes, or resources in waters deeper than 200 meters or in tropical mesophotic environments. Projects can entail conducting ocean exploration (e.g., mapping and characterizing ocean habitats, combining seismic and acoustic methods), advancing ocean exploration through the use or development of novel technologies (e.g., autonomous systems, nondestructive sensors, artificial intelligence/machine learning), and/or analysis of ocean exploration datasets or samples that already exist and are publicly accessible. NOAA Ocean Exploration is particularly interested in projects that explore the physical, chemical, and biological environments and processes in the deep oceanic water column and projects that will improve genetic libraries for species-level environmental DNA (eDNA) analysis of deep-sea species. All proposals must demonstrate how the proposed project relates to at least one of the exploration variables identified by NOAA Ocean Exploration (https://oceanexplorer.noaa.gov/data/publications/exploration-variables.html).MARITIME HERITAGE: Maritime Heritage proposals should address the exploration for significant maritime heritage resources that improve our understanding of the past and inform decisions about management and preservation. Maritime heritage projects can be conducted at any water depth. NOAA Ocean Exploration is particularly interested in proposals that target conflict archaeology, incorporate Indigenous knowledge, or perform wide-area searches in areas poorly mapped for maritime heritage. NOAA Ocean Exploration welcomes the use of innovative technology and/or methods for quantitative assessment of targets to improve archaeological site identification and documentation.Informational documents about this funding opportunity are on the NOAA Ocean Exploration website at https://oceanexplorer.noaa.gov/about/funding-opps/welcome.html.All links were valid as of the date of the publication of this notice. If updated links are needed, email [email protected] following lists are provided to aid preparation of pre-proposals and full proposals. Pre-Proposals (due May 30, 2024, at 4:59 p.m. ET)NOAA Ocean Exploration notice of funding opportunity cover sheetPre-proposal narrative, maximum two pagesDemographic information (optional) All applicants should submit proposals to [email protected]. | Full Proposals (due October 3, 2024, at 11:59 p.m. ET)Updated NOAA Ocean Exploration notice of funding opportunity cover sheetExecutive summary, maximum one pageProject narrative, maximum 15 pagesData and information sharing plan, maximum two pagesOutreach and education plan, maximum one pageStatement of diversity, equity, inclusion, and accessibility (DEIA), maximum one pagePrevious significant results for each principal and co-principal investigatorSummary of current funding support for each principal and co-principal investigatorCurriculum vitae, maximum two pages for each principal and co-principal investigatorBudget justification and budget tablesNegotiated indirect cost rate agreement (if applicable)National Environmental Policy Act (NEPA) questionnaireLetters of support (if applicable) from:The applicable state historic preservation office (SHPO; if the proposed project is in state waters)The tribal historic preservation office (THPO; if the proposed project is on federally recognized tribal lands)Indigenous communities identified as collaborating or cooperating with the proposed projectOther supporters (optional, e.g., ship time operators)Details about coordination with the National Oceanographic Partnership Program (NOPP), maximum one page (only applicable if the lead principal investigator is a federal employee)Forms (for nonfederal applicants only):Application for Federal Assistance (SF-424)Budget Information for Non-Construction Programs (SF-424A)Assurances for Non-Construction Programs (SF-424B)Disclosure of Lobbying Activities (SF-LLL)Certification Regarding Lobbying (CD511)Suggested reviewers (optional) Nonfederal applicants must submit all documents required for a full proposal individually through Grants.gov. | Federal applicants must email full proposals to [email protected]. | Applicant organizations must complete and maintain three registrations to be eligible to apply for or receive an award. These registrations include SAM.gov, Grants.gov, and eRA Commons. All registrations must be completed prior to the application being submitted. The complete registration process for all three systems can take 4 to 6 weeks, so applicants should begin this activity as soon as possible. If an eligible applicant does not have access to the internet, please contact the Agency Contacts (see in Section IV.A.) for submission instructions. | Prior to registering with eRA Commons, applicant organizations must first obtain a Unique Entity Identifier (UEI) from SAM.gov, if needed (see Section IV.C). Organizations can register with eRA Commons in tandem with completing their full SAM and Grants.gov registrations; however, all registrations must be in place by time of application submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
The “Connected Communities 2.0: Innovations to Manage Growing Transportation, Building, and Industrial Loads to the Grid” Funding Opportunity (FOA) issued by the Office of Energy Efficiency and Renewable Energy is designed to address major new loads from transportation, industry, and buildings on the electric grid by providing new tools for users, planners, and operators of the electric grid. This FOA has two major topical areas: Connected Communities 2.0, focused on grid edge technical measures in buildings, industry, and transportation to prepare the electric grid for these new loads, and improve the resilience of customers and the grid; and Smart Charge Management (SCM), focused on various unique urban, suburban, and rural use cases to build confidence in SCM as an effective approach for electric vehicles (EVs) to provide flexibility and value to the electric grid. The learnings from these projects should enable electric system planners and operators, strategic planners, regulators such as Public Utility Commissions (PUCs), and other stakeholders to understand and plan for new load growth and peak loads driven by electrification, growth in manufacturing, and new computing developments; and to plan for physical and cyber threats to reliability and resilience, while keeping costs affordable for customers and ratepayers. To achieve this end, the cohort of awarded projects will pursue three primary goals. First, the cohort will demonstrate how smart and coordinated management of EVs and other distributed energy resources (DERs), including the integration of efficiency, smart electrical panels, solar, heat pumps, controls, EV charging, and storage can together provide grid support, reduce system costs, and improve the economics of customer technology adoption, at a scale sufficient to enable confidence in wide-scale adoption. The second goal is to demonstrate approaches that enable acceptance by utilities, PUCs, and communities of smart charge management, grid-edge technical measures and innovative planning strategies as valid methods towards right sizing investments in the distribution system. The third and final major goal for the cohort is to demonstrate approaches towards improved resilience for communities, end-use customers, and the overall grid in the face of growing loads, extreme weather events, cyber threats, and increasing reliance on the electric grid through the use of grid edge technical measures. This FOA will award an estimated $65M, and is a cross office FOA co-funded by BTO, VTO, SETO, IEDO, GTO, and OE. The full Funding Opportunity Announcement (FOA) is posted on the EERE eXCHANGE website at https://eere-exchange.energy.gov. Applications must be submitted through the EERE eXCHANGE website to be considered for award. The applicant must first register and create an account on the EERE eXCHANGE website. A User Guide for the EERE eXCHANGE can be found on the EERE website https://eere-exchange.energy.gov/Manuals.aspx after logging in to the system. Information on where to submit questions regarding the content of the announcement and where to submit questions regarding submission of applications is found in the full FOA posted on the EERE Exchange website, https://eere-exchange.energy.gov. Please see full announcement at: https://ie-exchange.energy.gov/
Machine Learning and Artificial Intelligence (AI) are enabling extraordinary scientific breakthroughs in fields ranging from protein folding, natural language processing, drug synthesis, and recommender systems to the discovery of novel engineering materials and products. These achievements lie at the confluence of mathematics, statistics, engineering and computer science, yet a clear explanation of the remarkable power and also the limitations of such AI systems has eluded scientists from all disciplines. Critical foundational gaps remain that, if not properly addressed, will soon limit advances in machine learning, curbing progress in artificial intelligence. It appears increasingly unlikely that these critical gaps can be surmounted with increased computational power and experimentation alone. Deeper mathematical understanding is essential to ensuring that AI can be harnessed to meet the future needs of society and enable broad scientific discovery, while forestalling the unintended consequences of a disruptive technology. The National Science Foundation Directorates for Mathematical and Physical Sciences (MPS), Computer and Information Science and Engineering (CISE), Engineering (ENG), and Social, Behavioral and Economic Sciences (SBE) will jointly sponsor research collaborations consisting of mathematicians, statisticians, computer scientists, engineers, and social and behavioral scientists focused on the mathematical and theoretical foundations of AI. Research activities should focus on the most challenging mathematical and theoretical questions aimed at understanding the capabilities, limitations, and emerging properties of AI methods as well as the development of novel, and mathematically grounded, design and analysis principles for the current and next generation of AI approaches. Specific research goals include: establishing a fundamental mathematical understanding of thefactors determining the capabilities and limitations of current and emerging generations of AI systems, including, but not limited to, foundation models, generative models, deep learning, statistical learning, federated learning, and other evolving paradigms; the development of mathematically grounded design and analysis principles for the current and next generations of AI systems; rigorous approaches for characterizing and validating machine learning algorithms and their predictions; research enabling provably reliable, translational, general-purpose AI systems and algorithms; encouragement of new collaborations across this interdisciplinary research community and from diverse institutions. The overall goal is to establish innovative and principled design and analysis approaches for AI technology using creative yet theoretically grounded mathematical and statistical frameworks, yielding explainable and interpretable models that can enable sustainable, socially responsible, and trustworthy AI.
The role of the deputy warden in a correctional facility is integral to its efficient operation and management. As the second in command to the warden, the deputy warden is delegated full authority and responsibility for carrying out directives of the federal and state courts and the attorney general. The deputy warden is responsible for ensuring operational continuity, enhancing leadership and management, ensuring the safety and security of both staff and those persons in custody and enforcing policies and procedures to uphold compliance and accountability within the facility. | In essence, the deputy warden serves as the anchor in upholding the agency’s mission, fostering a safe and secure environment for all stakeholders and contributing to the successful rehabilitation and reintegration of individuals within the criminal justice system. Effective leadership, strong decision-making skills, dedication to justice, and accountability are essential in developing the leadership of deputy wardens to ensure that correctional facilities operate effectively.The VILT and e-course will be a valuable resource for deputy wardens, offering guidance on new and ongoing challenges relative to the field of corrections. The VILT and e-course will incorporate modern aesthetics and technology, including situational narratives, video clips, and engaging activities to provide relevant content on the emerging issues and persistent correctional challenges that an incoming deputy warden/second in command will encounter.
This program will provide funding to eligible state governments non-competitively, by formula to make awards to small and medium manufacturers to perform conversion projects to produce electric vehicles in accordance with Section 50143 of the Inflation Reduction Act (IRA).
The FY24 KCRP Idea Development Award is intended to support innovative ideas and high-impact approaches, based on scientifically sound evidence, to move toward the KCRP vision of eliminating kidney cancer. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. Personnel on the proposed team should have a strong background in kidney cancer research.The following are significant features of this award mechanism:Research Approach: The scientific rationale and experimental methodology should demonstrate critical understanding and in-depth analysis of kidney cancer. Experimental strategies may be novel or may be based on strong rationale derived from previously published data and/or presented preliminary data. The feasibility of the research design and methods should be well-defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Additionally, resources should be identified, and availability supported through documentation. Identification of potential problems and pitfalls with alternate approaches should be addressed. A statistical analysis plan for the proposed research should be included, if applicable, as well as a power analysis to support the design and sample size.Preliminary Data: Preliminary data are required but need not be in kidney cancer. Preliminary data may include unpublished or published results from the laboratory of the Principal Investigator (PI) or collaborators named on the application and/or data from the published literature relevant to kidney cancer.Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other creative qualities. This may include high-risk, potentially high-gain, approaches to kidney cancer research, provided the application demonstrates the potential for significant impact on the field of research, patient care, and/or quality of life. Research that is likely to yield only an incremental advance is not considered innovative.Impact: Proposed research projects should address a central critical issue or question in kidney cancer research or clinical care. High-impact research will, if successful, significantly advance current methods and concepts in at least one of the FY24 KCRP Focus Areas.Personnel: Personnel are considered a crucial element of the FY24 KCRP Idea Development Award. The application should demonstrate the investigators’ experience in kidney cancer through the PI’s background, the research team, and/or through collaboration. Collaborations should be documented.The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement:• All Applications: Innovative, high-risk/high-reward and/or preclinical research that is supported by preliminary and/or published data.Partnering PI Option: The FY24 KCRP supports collaborative research to bring a new perspective to kidney cancer research and/or facilitate progress in the field by combined efforts. Therefore, the KCRP Idea Development Award mechanism includes a Partnering PI Option, which is structured so that two investigators, each of whom will be designated as a PI and receive a separate award, will work synergistically on a single project. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should collaborate to develop a synergistic project addressing one or more of the FY24 KCRP Idea Development Award Focus Areas. Applications submitted by a mentor and trainee as Initiating PI and Partnering PI do not meet the intent of the Partnering PI Option. Multidisciplinary and multi-organizational projects are allowed. Initiating and Partnering PIs each have different submission requirements, as described in Section II.D.2, Content and Form of the Application Submission; however, both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. It should be clear that both investigators have had an equal level of intellectual input and effort in developing the application. If recommended for funding, each PI will be named to an individual award within the recipient organization.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and the American public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under §46.104(d)(4) of the Common Rule.Organizational-Level Emphasis:The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research and addresses the FY24 KCRP strategic goals and focus areas described in Section II.A.1 and Section II.A.2.Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Women’s Health: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/ 05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities.Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and the American public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP IDA should not exceed $800,000. The anticipated combined direct costs budgeted for the entire period of performance for an FY24 KCRP Idea Development Award – Partnering PI Option will not exceed $1.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $18.56M to fund approximately 13 Idea Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.
The FY24 PRCRP CSCCA supports a transdisciplinary collaboration of scientists, clinicians, and consumer advocates, working to illuminate and address urgent and complex issues of importance in cancer research. This mechanism seeks to promote novel approaches to ending cancer through convergent science cancer research. Convergent science as defined by the National Science Foundation (https://www.nsf.gov/od/oia/convergence/index.jsp) “is a means of solving vexing research problems, in particular, complex problems focusing on societal needs. It entails integrating knowledge, methods, and expertise from different disciplines and forming novel frameworks to catalyze scientific discovery and innovation.” Convergent science taps into a variety of disciplines to answer the issues in cancer (i.e., prevention, diagnosis/detection, treatment, quality of life, disparities) including but not limited to biomedical sciences, data science, engineering, psychology, and chemistry. Convergent science breaks down the barriers of cancer research and builds a whole answer with tools from different areas of expertise. The CSCCA application must identify one of the FY24 Overarching Challenges as a unifying Focal Point for the consortium, and a minimum of three research projects addressing the Focal Point. Additionally, applicants must clearly define how their application investigates at least three different FY24 PRCRP Topic Areas. For example, brain cancer, neuroblastoma, and pediatric brain tumors are three of the FY24 PRCRP Topic Areas and would be acceptable. Three different types of pediatric brain tumors (i.e., pediatric medulloblastomas, diffuse intrinsic pontine glioma, and pediatric astrocytomas) are not considered three different FY24 PRCRP Topic Areas and would not be acceptable. The proposed Convergent Science consortium should demonstrate the potential to catalyze scientific discovery and innovation, significantly advance cancer research, and have a profound positive impact on the lives of cancer patients or those at risk for cancer including Service Members, their Families, other military beneficiaries, and the American public. Consumer advocates should be integrated into and play an active role in the leadership and decision-making for the consortium. An individual advocate can only serve as an advisor and team member at one Research Site. The advocates must be cancer patients or a caretaker of patients from the FY24 PRCRP Topic Areas, be active in a cancer advocacy organization, and possess a high level of familiarity with current issues in cancer research. The advocates’ role should be independent of their employment with a participating institution.
NIC has noted a growing trend among jurisdictions aiming to establish or enhance CJCCs to optimize theircriminal justice systems. When fully leveraged, CJCCs serve as powerful entities that harness data-driveninsights to address various challenges. They play a crucial role in managing jail populations more effectivelyand advancing reentry programs, ultimately contributing to a more streamlined and effective justice system.By integrating diverse stakeholders and utilizing comprehensive data, CJCCs can drive meaningfulimprovements in both operational efficiency and outcomes for individuals navigating the justice system. Asa result, NIC wants to invest in local CJCCs that demonstrate a desire to implement NIC-identified bestpractices.
NSF Astronomy and Astrophysics Postdoctoral Fellowships provide an opportunity for highly qualified, recent doctoral scientists to carry out an integrated program of independent research and education. Fellows may engage in observational, instrumental, theoretical, laboratory or archival data research in any area of astronomy or astrophysics, in combination with a coherent educational plan for the duration of the fellowship. The program supports researchers for a period of up to three years with fellowships that may be taken to eligible host institutions of their choice. The program is intended to recognize early-career investigators of significant potential and to provide them with experience in research and education that will establish them in positions of distinction and leadership in the scientific community.
The Historically Black Colleges and Universities - Excellence in Research (HBCU-EiR) program was established in response to direction provided in the Senate Commerce and Justice, Science and Related Agencies Appropriations Subcommittee Report (Senate Report 115-139), and is built on prior and continuing efforts by the National Science Foundation (NSF) to strengthen research capacity at Historically Black Colleges and Universities (HBCUs). This report provided guidance to NSF to establish the HBCU Excellence in Research program "to provide opportunities for both public and private HBCUs, particularly for those who have not been successful in larger NSF Research & Related Activities competitions, in order to stimulate sustainable improvement in their research and development capacity" (https://congress.gov/congressional-report/115th-congress/senate-report/139/1). EiR supports such capacity building by funding research projects aligned with NSF's research programs. The program aims to establish stronger connections between researchers at HBCUs and NSF's research programs.
Through this cooperative agreement, NIC seeks to develop a specialized training curriculum for criminal justice coordinating council chairs and executive directors. This curriculum must be developed using the ITIP model for curriculum design. This model is grounded in research and promotes the principles of ADDIE (analyze, design, develop, implement, and evaluate). NIC has developed an ITIP Toolkit to assist organizations in meeting this requirement. In addition, this curriculum should follow a blended training model with both VILT (virtual instructor-led training components) and ILT (instructor-led training) components. The training should be at least 30-hours in length.
The FY24 PRCRP ACCCTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY24 PRCRP Topic Areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of- concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials to determine efficacy in relevant patient populations. Funding from this award mechanism must support a clinical trial. Key aspects of the PRCRP Award Mechanism: · Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 12 months after the award date or 18 months after the award date for studies regulated by the Regulatory Agency. · Impact: The proposed intervention(s) to be tested should offer significant potential for advancing to the next stage of clinical study, transition of results to fielded science, or improve the standard of care for at least one of the FY24 PRCRP Topic Areas and address one of the FY24 PRCRP Military Health Focus Areas and one of the FY24 PRCRP Overarching Challenges. The impact of the intervention should include considerations of quality of life and supportive care during the trial. · Supportive preclinical data are required: Inclusion of supportive preclinical data relevant for the clinical trial is required. No proposed preclinical research to support an IND/ IDE application is allowed. The data presented to support the initiation of a clinical trial is required. No animal work is allowed. · Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement. · Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. · Personnel and Environment: The application should demonstrate the study team’s expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of FDA processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in 21 CFR 312, Subpart D, are fulfilled. · Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.
The KCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of kidney cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.Key aspects of the KCRP Clinical Trial Award Mechanism:• Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 12 months after the award date or 18 months after the award date for studies regulated by the Regulatory Agency.• Preliminary Data Are Required: Inclusion of preliminary data relevant to the proposed clinical trial is required.• Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement.• Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study.• Personnel and Environment: The application should demonstrate the study team’s expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of U.S. Food and Drug Administration (FDA) processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in Code of Federal Regulations, Title 21, Part 312, Subpart D (21 CFR 312.D), are fulfilled.• Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.Organizational-Level Emphasis:The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research and addresses the FY24 KCRP strategic priorities and/focus areas described in Section II.A.1 and Section II.A.2.Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Women’s Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women’s health outcomes and/or advancing knowledge for women’s health.Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities.Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Funding from this award mechanism must support a clinical trial. A clinical trial is defined in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Applicants seeking funding for research that does not meet this definition should consider one of the other FY24 KCRP program announcements being offered.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international regulatory agency unless otherwise noted.If the proposed clinical trial involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an Investigational New Drug (IND) application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an Investigational Device Exemption (IDE), or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency by the Clinical Trial Award application submission deadline. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP CTA should not exceed $2,000,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $6.4M to fund approximately two Clinical Trial Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.
Perhaps no other intervention has attracted more attention across the criminal justice system than cognitivebehavioral therapy (CBT). First widely used in the latter half of the 20th century, as large numbers of peoplewith mental illness were deinstitutionalized and treated in community settings, CBT has since found its wayinto nearly every aspect of the justice system, often supplementing, or displacing other programs andinterventions. CBT assumes that most people can become conscious of their own thoughts and behaviorsand then make positive changes to them. A person's thoughts are often the result of experience, and behavioris often influenced and prompted by these thoughts. In addition, thoughts may sometimes become distortedand fail to reflect reality accurately. Practitioners today use CBT to reduce recidivism among adults andjuveniles, help victims deal with the aftermath of crimes, and address substance abuse, depression, violence,and other problematic behavior. CBT programs help individuals in corrections improve their social skills,means-ends problem solving, critical reasoning, moral reasoning, cognitive style, self-control, impulsemanagement, and self-efficacy. Effective facilitators are crucial to assisting to make these improvementsand reductions. The ideal skills for group facilitators include empathy, knowledge of facilitation/teachingtechniques, understanding group processes and interpersonal interactions, the ability to control a group ofjustice-involved adults and at-risk youth, and the ability to challenge individuals through non-coercivemeans. Almost without exception, studies of cognitive behavioral programs point to proper training as a keyfactor in achieving desired program outcomes. Training is the starting point for successful facilitators.
The FAST Act established the NSFLTP Program. Under Section § 1123(a) of the FAST Act, the purpose of the NSFLTP Program is to provide funding to construct, reconstruct, or rehabilitate nationally significant Federal Lands and Tribal transportation projects. | Grants under the NSFLTP Program are to be awarded on a competitive basis to projects of national significance for construction, reconstruction, or rehabilitation of transportation facilities within, adjacent to, or providing access to Federal or Tribal Lands.
The purpose of the Mathematical Sciences Postdoctoral Research Fellowships (MSPRF) is to support future leaders in mathematics and statistics by facilitating their participation in postdoctoral research environments thatwill have maximal impact on their future scientific development. There are two options for awardees: Research Fellowship and Research Instructorship. Awards will support research in areas of mathematics and statistics, including applications to other disciplines.
Please note that this program requests optional Notices of Intent, which are due via NSPIRES by September 13, 2024. See the full posting on NSPIRES for details. | Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) – 2024 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2024. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates (Tables 2 and 3), a table that provides a very top level summary of proposal contents (Table 1), and the full text of the ROSES-2024 "Summary of Solicitation", may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2024. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2024table2 and http://solicitation.nasaprs.com/ROSES2024table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH24ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on “C.8 Lunar Data Analysis Program (.pdf)” to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read “C.1 Planetary Science Research Program Overview (.pdf)” from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2024 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at [email protected], but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2024 blog feed for amendments, clarifications, and corrections to at https://science.nasa.gov/researchers/solicitations/roses-2024/, and (3) The ROSES-2024 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).
The purpose of the Mathematical and Physical Sciences Ascending Postdoctoral Research Fellowship (MPS-Ascend) program is to support postdoctoral Fellows who will broaden the participation of members of groups that are historically excluded and currently underrepresented in MPS fields in the U.S., defined in this solicitation as Blacks or African Americans, Hispanics, Latinos, Indigenous and Native Americans, Alaska Natives, Native Hawaiians and other Native Pacific Islanders,as future leaders in MPS fields. The program is intended to recognize beginning investigators of significant potential and provide them with experience in research that will broaden perspectives, facilitate interdisciplinary interactions, and help broaden participation within MPS fields. The program funds postdoctoral Fellows in research environments that will have maximal impact on their future scientific development and facilitates their transition into a faculty appointment. Awards will support research in any scientific area within the purview of the five MPS Divisions: the Divisions of Astronomical Sciences (AST), Chemistry (CHE), Materials Research (DMR), Mathematical Sciences (DMS), and Physics (PHY). Fellowships are awards to individuals, not institutions, and are administered by the Fellows. | |
This notice (HRSA-25-063)-announces the opportunity to apply for funding for the Ending the HIV Epidemic in the U.S. – Ryan White HIV/AIDS Program Parts A and B cooperative agreement. The purpose of this initiative is to focus resources in 48 counties, Washington, D.C., San Juan, Puerto Rico (PR), and seven states with the highest incidence or burden of HIV to implement effective and innovative strategies, interventions, approaches, and services to reduce new HIV infections in the United States. The Ending the HIV Epidemic in the U.S. (hereafter referred to as the “EHE initiative”) focuses on four key strategies: •Diagnose all people with HIV as early as possible; •Treat people with HIV rapidly and effectively to reach sustained viral suppression; •Prevent new HIV transmissions by using proven interventions; and •Respond quickly to potential HIV outbreaks to get needed prevention and treatment services to people who need them. HRSA and the Centers for Disease Control and Prevention (CDC), along with the National Institutes of Health (NIH) Centers for AIDS Research (CFARs), the Indian Health Service (IHS), Department of Housing and Urban Development (HUD), and the Substance Abuse and Mental Health Services Administration (SAMHSA) are collaborating on implementation of these key strategies. HRSA’s responsibilities include increasing testing and prevention among Health Center Program patients, providing access to HIV care and treatment through the RWHAP and Health Center Program, and linking people with HIV, newly diagnosed or re-identified through testing programs, to care, and responding to outbreaks. For the Ryan White Program, the EHE initiative expands the program’s ability to meet the needs of clients, specifically focusing on linking people with HIV who are either newly diagnosed, diagnosed but currently not in care, or are diagnosed and in care but not yet virally suppressed, to the essential HIV care, treatment, and support services needed to help them reach viral suppression.
The purpose of this funding opportunity announcement (FOA) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development.
This notice announces the opportunity to apply for funding for the Ending the HIV Epidemic in the U.S. – Technical Assistance Provider (TAP) (HRSA-25-064) and Ending the HIV Epidemic in the U.S. – Systems Coordination Provider (SCP) (HRSA-25-065), as administered by the HRSA HIV/AIDS Bureau (HAB) in conjunction with the Ryan White HIV/AIDS Program (RWHAP) Parts A and B. The purpose of this program is to fund TA and systems coordination for the 48 counties, Washington, D.C., San Juan, Puerto Rico (PR), and seven states (hereafter referred to as “jurisdictions”) identified in and funded through HRSA-20-078 (the funded entities hereafter referred to as “recipients”). The overarching goal for this initiative is to reduce new HIV infections in the United States. To reduce the new HIV infections in the United States, the EHE initiative focuses on four key strategies: •Diagnose all people with HIV as early as possible; •Treat people with HIV rapidly and effectively to reach sustained viral suppression; •Prevent new HIV transmissions by using proven interventions, including pre-exposure prophylaxis (PrEP) and syringe services programs (SSPs); and •Respond quickly to potential HIV outbreaks to get needed prevention and treatment services to people who need them. The role of HRSA HAB and its recipients under HRSA-25-063 is to focus on Treat and Respond. These recipients are encouraged to be creative as they design ways to use EHE initiative funds in conjunction with the current RWHAP Parts A and B systems of care and treatment to end the HIV epidemic in their jurisdictions. The funding directed to the recipients under HRSA-25-063 will allow jurisdictions to implement emerging, evidenced-informed, and/or evidence-based interventions to increase linkage, engagement, and retention in care in addition to funding the additional care and treatment needs of the newly identified and re-engaged individuals. There will be multiple streams of federal resources focused on jurisdictions to help them meet the goals of the EHE initiative. These new and/or expanded resources are in addition to the existing federal HIV resources, creating the need for coordination to ensure the maximum impact of all available resources. HRSA will award one cooperative agreement for each of the following announcement numbers: The TAP funded under HRSA-25-064 is responsible for providing TA to the recipients of HRSA-25-063 on implementation of work plan activities, innovative approaches, and interventions. The SCP funded under HRSA-25-065 is responsible for assisting HRSA-25-063 recipients in coordinating and integrating their initiative plans, funding sources, and programs with the existing HIV care delivery systems. In addition, the SCP will assist in identifying existing and new stakeholders, as well as collate and disseminate best practices, innovative approaches, and interventions identified by the TAP that will advance recipients’ progress in meeting the goals of the initiative.
This notice announces the opportunity to apply for funding for the Ending the HIV Epidemic in the U.S. – Technical Assistance Provider (TAP) (HRSA-25-064) and Ending the HIV Epidemic in the U.S. – Systems Coordination Provider (SCP) (HRSA-25-065), as administered by the HRSA HIV/AIDS Bureau (HAB) in conjunction with the Ryan White HIV/AIDS Program (RWHAP) Parts A and B. The purpose of this program is to fund TA and systems coordination for the 48 counties, Washington, D.C., San Juan, Puerto Rico (PR), and seven states (hereafter referred to as “jurisdictions”) identified in and funded through HRSA-20-078 (the funded entities hereafter referred to as “recipients”). The overarching goal for this initiative is to reduce new HIV infections in the United States. To reduce the new HIV infections in the United States, the EHE initiative focuses on four key strategies: •Diagnose all people with HIV as early as possible; •Treat people with HIV rapidly and effectively to reach sustained viral suppression; •Prevent new HIV transmissions by using proven interventions, including pre-exposure prophylaxis (PrEP) and syringe services programs (SSPs); and •Respond quickly to potential HIV outbreaks to get needed prevention and treatment services to people who need them. The role of HRSA HAB and its recipients under HRSA-25-063 is to focus on Treat and Respond. These recipients are encouraged to be creative as they design ways to use EHE initiative funds in conjunction with the current RWHAP Parts A and B systems of care and treatment to end the HIV epidemic in their jurisdictions. The funding directed to the recipients under HRSA-25-063 will allow jurisdictions to implement emerging, evidenced-informed, and/or evidence-based interventions to increase linkage, engagement, and retention in care in addition to funding the additional care and treatment needs of the newly identified and re-engaged individuals. There will be multiple streams of federal resources focused on jurisdictions to help them meet the goals of the EHE initiative. These new and/or expanded resources are in addition to the existing federal HIV resources, creating the need for coordination to ensure the maximum impact of all available resources. HRSA will award one cooperative agreement for each of the following announcement numbers: The TAP funded under HRSA-25-064 is responsible for providing TA to the recipients of HRSA-25-063 on implementation of work plan activities, innovative approaches, and interventions. The SCP funded under HRSA-25-065 is responsible for assisting HRSA-25-063 recipients in coordinating and integrating their initiative plans, funding sources, and programs with the existing HIV care delivery systems. In addition, the SCP will assist in identifying existing and new stakeholders, as well as collate and disseminate best practices, innovative approaches, and interventions identified by the TAP that will advance recipients’ progress in meeting the goals of the initiative.
The FY24 RTRP Advanced Technology Development Award is intended to support research critical for the translation of promising preclinical findings into products focused on reconstructive transplantation.Proposed research and products to be developed may be materiel products such as drugs, biologic agents, devices, or knowledge-based products such as technical reports and clinical practice guidelines that inform clinical/operational decisions and promote evidence-based changes in clinical practice and standard of care. Proposed research may include preclinical studies in animal models, human subjects, or human anatomical substances, as well as correlative studies associated with an existing clinical trial.Important aspects of this award mechanism include:• Study Design and Feasibility: The proposed study design should be clearly described, rigorous, well-integrated, and support maximal reproducibility and translational feasibility. A statistical plan with appropriate power analysis should be included, if applicable. It should be clear how the proposed study design of this project will position the product for the next phase of development as described in the post-award Transition Plan (Attachment 9). If a model system is included in the research, it should be appropriate for the study and applicable to VCA.• Impact/Military Relevance: The short- and long-term impacts of the proposed research should be clearly articulated. Projects must address at least one of the FY24 RTRP Advanced Technology Development Award Focus Areas listed in Section II.A.1 above. All products to be developed must be responsive to the health care needs of military Service Members and/or Veterans recovering from traumatic injury, and/or their Family members, caregivers, or clinicians, as well as the general public. Collaboration with military and VA researchers and clinicians is encouraged but not required.• Transition Plan: The post-award Transition Plan (Attachment 9) should include potential funding and resources and show how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the successful completion of this award. A regulatory strategy as applicable to the proposed research/product should also be included.• Preliminary Data: Proof of concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, must already be established. Preliminary and/or published data that are relevant to reconstructive transplantation and support the rationale for the proposed study must be included (these data may be unpublished if from a member of the research team or from the published literature).Important Note: Leveraging novel findings from solid organ transplant research for testing in a VCA setting is acceptable if the rationale and benefits for doing so are appropriately explained and justified. For example, it should be clear why the anticipated result might be different in VCA, or why it is important to confirm the result is the same in VCA, or why repeating the study in a VCA setting could lead to new mechanistic insights or a better understanding of unique aspects of VCA.Advancing Women’s Health Research and Innovation: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women’s health outcomes and/or advancing knowledge for women's health. The RTRP therefore encourages research that addresses how various aspects of reconstructive transplant affect women uniquely, disproportionately, or differently from men.Multiple Principal Investigator (PI) Option: The Advanced Technology Development Award includes an option for up to four PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s). All PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI(s), refer to Section II.D.2, Content and Form of the Application Submission.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Use of Department of Defense (DOD) or VA Resources: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the VA, and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.For research involving animals, human subjects, human anatomical substances, or human cadavers, please see to the General Application Instructions, Appendix 6, for more information.Clinical trials are not allowed under this funding opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research is allowed under this funding opportunity. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under §46.104(d)(4) of the Common Rule.In-Progress Review: The RTRP holds annual In-Progress Review meetings in a virtual setting as a forum for award performers to present progress updates to the Programmatic Panel and RTRP staff. Award recipients may receive an invitation to present their project at one of these meetings during the period of performance of their award.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 RTRP Advanced Technology Development Award should not exceed $1.0M for single PI applications and $1.5M for applications submitted under the Multiple PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $3.5M to fund approximately three Advanced Technology Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030. |
DE-FOA-0003323: Water Power Innovation Network AMENDMENT 000002: The purpose of this modification is to provide clarity to the following areas and update the Statement of Project Objectives template: • Added language that clarifies the proposed programming and services will be further developed during Budget Period 1. • Added language that applicants’ proposed programs should provide incubation, acceleration, and commercialization support to entrepreneurs and small businesses in water power. • Added language to the Content and Form of the Concept Paper and Full Application that clarifies the proposed program could be a new water power incubator or accelerator program, or could be an existing incubator or accelerator program that will be expanded upon in water power. • Technical Volume Work Plan to focus on Budget Period 1. An associated SOPO template is provided. • The Down-Select deliverable, Updated Budget, SOPO, and Project Schedule, should be updated to include information for Budget Period 2. AMENDMENT 000001: The purpose of this modification is to adjust the timeline for this FOA, which includes changes to the following dates: • Submission Deadline for Concept Papers • Submission Deadline for Full Applications • Expected Date for EERE Selection Notifications • Expected Timeframe for Award Negotiations The U.S. Department of Energy’s (DOE) Water Power Technologies Office (WPTO) is issuing this $4.8 million funding opportunity announcement (FOA) “Water Power Innovation Network” to support business creation, entrepreneurship, and regional innovation for water power systems and solutions. WPTO enables research, development, and testing of emerging technologies to advance marine energy as well as next-generation hydropower and pumped storage systems for a flexible, reliable grid. Through this FOA, WPTO seeks to fund new and/or expanded incubator or accelerator programs that enable entrepreneurship and accelerate water power innovation, business creation, and growth in communities and regions throughout the United States. Through this FOA, new and/or expanded incubators and accelerators in water power will be able to collaborate with one another and build a stronger water power innovation network in support of accelerating water power technologies to market. Topic Area 1: Water Power Incubation and Acceleration. This topic area will fund programs that accelerate the commercialization and adoption of water power systems and solutions through incubation and acceleration programming and services that support entrepreneurs and small businesses in marine energy and/or hydropower. Questions regarding the FOA must be submitted to [email protected]. To view the entire FOA document, visit the EERE Exchange Website at https://eere-exchange.energy.gov.
The FY24 RTRP Idea Discovery Award is intended to support innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods relevant to reconstructive transplant. The outcome of research supported by this award should be the generation of robust data that can be used as a foundation for new avenues of scientific investigation.Important aspects of this award mechanism include:• Innovation: The proposed project should be novel and innovative. Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. If the proposed project is building upon established research performed in solid tissue organs, there must be justification for how the proposed theory is novel. Research that is an incremental advance upon published data or a logical progression of an already established research project is not considered innovative and will not be considered for funding under this award mechanism.Important Note: Leveraging novel findings from solid organ transplant research for testing in a VCA setting is acceptable if the rationale and benefits for doing so are appropriately explained and justified. For example, it should be clear why the anticipated result might be different in VCA, or why it’s important to confirm the result is the same in VCA, or why repeating the study in a VCA setting could lead to new mechanistic insights or a better understanding of unique aspects of VCA.• Hypothesis and Rationale: The proposed research project should include a well-formulated testable hypothesis based on strong scientific rationale and study design. If a model system is included in the research, it should be appropriate for the study and applicable to VCA.• Preliminary Data: Inclusion of preliminary and/or published data that support the scientific rationale or evidence that the proposed work can be completed are required; however, the proposed work should be innovative and untested.• Impact: Applications must address at least one of the FY24 RTRP IDA Focus Areas. The anticipated outcome(s)/product(s), including material and/or knowledge products, should be clearly articulated, as should the anticipated long-term gains from this research trajectory.• Military Relevance: All projects should be responsive to the health care needs of military Service Members and/or Veterans recovering from traumatic injury, and/or their Family members, caregivers, or clinicians, as well as the general public. Collaboration with military researchers and clinicians is encouraged.Advancing Women’s Health Research and Innovation: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women’s health outcomes and/or advancing knowledge for women's health. The RTRP therefore encourages research that addresses how various aspects of reconstructive transplant affect women uniquely, disproportionately, or differently from men.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Use of Department of Defense (DOD) or VA Resources: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the VA, and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.For research involving animals, human subjects, human anatomical substances, or human cadavers, please see to the General Application Instructions, Appendix 6, for more information.Because the FY24 RTRP Idea Discovery Award is designed for preliminary investigations, projects involving human subjects or anatomical substances will not be supported unless they are exempt under Title 32, Code of Federal Regulations, Part 219, Section 104(d) (32 CFR 219.104[d]) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. Studies that do not qualify for exempt status or expedited review will be administratively withdrawn and will not be funded. Therefore, clinical trials are not allowed under this funding opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research is allowed under this funding opportunity. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under §46.104(d)(4) of the Common Rule.In-Progress Review: The RTRP holds annual In-Progress Review meetings in a virtual setting as a forum for award performers to present progress updates to the Programmatic Panel and RTRP staff. Award recipients may receive an invitation to present their project at one of these meetings during the period of performance of their award.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 RTRP Idea Discovery Award should not exceed $500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.DOD FY24 Reconstructive Transplant Idea Discovery Award 7Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $2.5M to fund approximately five Idea Discovery Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.
The FY24 RTRP Investigator-Initiated Research Award is intended to support studies that have the potential to make an important contribution to reconstructive transplant research, patient care, and/or quality of life. Though the RTRP Investigator-Initiated Research Award mechanism supports groundbreaking research, all projects must demonstrate solid scientific rationale with military-relevant utility. Important aspects of this award mechanism include:• Study Design and Feasibility: The proposed study design should be clearly described, rigorous, and support maximal reproducibility and translational feasibility. A statistical plan with appropriate power analysis should be included, as applicable. If a model system is included in the research, it should be appropriate for the study and applicable to VCA.• Impact: The short- and long-term impact of the proposed research should be clearly articulated. Projects must address at least one of the FY24 RTRP Investigator-Initiated Research Award Focus Areas.• Military Relevance: All projects must be responsive to the health care needs of military Service Members and/or Veterans recovering from traumatic injury, and/or their Family members, caregivers, or clinicians, as well as the general public. Collaboration with military researchers and clinicians is encouraged, but not required.• Preliminary Data: Observations that drive a research idea may be derived from laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Preliminary and/or published data that are relevant to reconstructive transplantation and support the rationale for the proposed research must be included.Important Note: Leveraging novel findings from solid organ transplant research for testing in a VCA setting is acceptable if the rationale and benefits for doing so are appropriately explained and justified. For example, it should be clear why the anticipated result might be different in VCA, or why it’s important to confirm the result is the same in VCA, or why repeating the study in a VCA setting could lead to new mechanistic insights or a better understanding of unique aspects of VCA.Investigator-Initiated Research Award applications may focus on any phase of research from basic through translational, including preclinical studies in animal models, and clinical research in human subjects or human anatomical substances, as well as correlative studies associated with an existing clinical trial.Advancing Women’s Health Research and Innovation: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women’s health outcomes and/or advancing knowledge for women's health. The RTRP therefore encourages research that addresses how various aspects of reconstructive transplant affect women uniquely, disproportionately, or differently from men.Multiple Principal Investigator (PI) Option: The Investigator-Initiated Research Award includes an option for up to four PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s). All PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI(s), refer to Section II.D.2, Content and Form of the Application Submission.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Use of Department of Defense (DOD) or VA Resources: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the VA, and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.For research involving animals, human subjects, human anatomical substances, or human cadavers, please see to the General Application Instructions, Appendix 6, for more information.Clinical trials are not allowed under this funding opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research is allowed under this funding opportunity. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under §46.104(d)(4) of the Common Rule.In-Progress Review: The RTRP holds annual In-Progress Review meetings in a virtual setting as a forum for award performers to present progress updates to the Programmatic Panel and RTRP staff. Award recipients may receive an invitation to present their project at one of these meetings during the period of performance of their award.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 RTRP Investigator-Initiated Research Award should not exceed $1.0M for single PI applications and $1.5M for applications submitted under the Multiple PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $4.0M to fund approximately three Investigator-Initiated Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.
The intent of the FY24 RTRP Qualitative Research Validation and Implementation Award mechanism is to support the continued investigation and further expansion of highly impactful resources for the VCA community that were developed through RTRP-funded qualitative research studies. These resources may benefit individuals throughout the VCA community, including those who are considering or who have already received reconstructive transplant surgery, as well as caregivers, potential donors and their families, and clinicians. The RTRP recognizes that these resources are not yet deployable products and require further research to ready them for clinical and community use. Proposed studies should expand previously funded qualitative research for the purposes of validating a VCA resource and/or investigating the most appropriate and effective methods and best practices for disseminating and/or implementing the resource. Important Note: This award mechanism is intended to support validation and implementation research, but not the costs of implementation itself.Qualitative research is a form of social inquiry that focuses on understanding how people interpret and make sense of their experiences and the world in which they live. Observations that drive a research idea may be derived from basic discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Qualitative research is intended to be exploratory, open-ended, and unbiased. The information gathered should be meaningful and culturally appropriate to the participant, unanticipated (not hypothesis-based) by the research team, and rich and explanatory in nature.Implementation science is defined as the scientific study of methods and strategies to adopt and integrate evidence-based health interventions, resources, etc., into clinical and community settings in order to improve patient outcomes and benefit population health. Implementation research may use a variety of qualitative and quantitative research methods to determine the most appropriate and effective way to transition interventions, resources, etc., into clinical practice, health policy, or everyday use. The research should be specific to the target population and environment and consider real-world factors and complexities, including an evolving landscape.Important aspects of this award mechanism include:• Qualitative Approach: The research approach should include primarily qualitative methods. Qualitative findings may lead the research in a more quantifiable direction, in which case a mixed methods approach is acceptable. The specific theoretical basis (e.g., interactionism, phenomenology, critical theory) for the study should be stated and should drive the framing of the research problem.• Preliminary data (required): Applications must include an Outcomes Statement (Attachment 9), which is a summary of the research previously funded, and a description of the research accomplishments, outcomes, and resource(s) developed from that award. Applications should provide an explanation of how these accomplishments, outcomes, and resource(s) provide the basis for the proposed research and how expansion of the original research ideas will address one or both of the FY24 RTRP Qualitative Research Focus Areas.• Study Design: The proposed study design, sampling technique, data collection, and recording method(s) should be appropriate to yield trustworthy, credible, robust, and confirmable results. The documentation of procedures, decisions, and rationale for decisions and conclusions should support consistency, dependability, and duplicability of results and prevent biases and preconceptions. The data analysis plan should be consistent with the research problem and theoretical basis for the study, and ongoing feedback from participants should be incorporated throughout the project, especially regarding interpretation of data and study conclusions. It should be clear how the proposed study design will position the resource(s) for the next phase of development or implementation as described in the post-award Implementation Plan (Attachment 10).• Impact: The short- and long-term impact of the proposed research should be clearly articulated. Projects must address one or both of the FY24 RTRP Qualitative Research Focus Areas.• Military Relevance: All projects must be responsive to the health care needs of military Service Members and/or Veterans recovering from traumatic injury, and/or their Family members, caregivers or clinicians, as well as the general public. Collaboration with military researchers and clinicians is encouraged, but not required.Advancing Women’s Health Research and Innovation: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women’s health outcomes and/or advancing knowledge for women’s health. The RTRP therefore encourages research that addresses how various aspects of reconstructive transplant affect women uniquely, disproportionately, or differently from men.Use of Department of Defense (DOD) or VA Resources: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, VA, and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Clinical trials are not allowed under this funding opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Clinical research is allowed under this funding opportunity. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under §46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 RTRP Qualitative Research Validation and Implementation Award should not exceed $500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $500,000 to fund approximately one Qualitative Research Validation and Implementation Award application. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.
The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (FOA #).
oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. In recent years, there have been significant advances in methods and technologies for the identification of novel targets, mechanisms, and pathways of interest to substance use disorders and in identification of probes and optimized compounds for developing novel therapeutic agents. This FOA is to enable investigators with knowledge in the emerging chemical, pharmacological, and drug discovery technologies to pursue innovative and transformative research on chemical and pharmacological aspects of substance use disorders.
Ethical considerations are intrinsic to the conduct of robotic and bionic device research. This Notice of Funding Opportunity (NOFO) invites applications that propose research on ethical questions associated with all stages of the design, testing, and/or implementation of bionic and robotic devices.
This initiative will solicit applications that propose the development and early stage validation of next generation humanized small animal models and/or human cellular microphysiological systems that improve the translational relevance of NeuroHIV models, specifically in the context of chronic HIV infection of the CNS in the modern antiretroviral therapy (ART) era under conditions of viral suppression.
This Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 10 years.
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions. Specifically, this NOFO solicits R33 applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. This NOFO will support studies to assess the ability of the unique patterns of host biology (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with probiotic usage to detect the improvement of probiotic responsiveness. Well-suited applications must offer rigorously designed mechanistic studies using relevant/innovative animal models or in human subjects. This NOFO is intended to support projects where potential host biological patterns that are correlated with probiotic usage have been identified, as demonstrated with supportive preliminary data, but require further mechanistic studies to test for their causality or predictability. Applicants pursuing early-stage research to identify host biological patterns that may affect probiotic health outcomes should consider the companion (R61/R33) NOFO PAR-AT-24-XXX (TEMP-25412).
The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.
The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Notice of Funding Opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities. For more information see BP MedTech website.
The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and multi-disciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address health and health care disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos. Multi-disciplinary research teams would be expected to meaningfully collaborate with key partners that must include at least one PI or MPI from institutions in Latin America.
This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research. The resource should be available to any qualified investigator, and should be highly quality controlled, and not duplicate resources available commercially or through other sources. Resources should be designed to provide services to the broad alcohol research community and should not be limited by any specific regional focus.
NIMH seeks applications for pilot research to adapt, optimize, and test empirically supported behavioral interventions that address common sleep problems in adolescents and young adults with or at risk for a mental health disorder. Pilot trials should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach in real world settings, and to conduct a preliminary test of the interventions impact on target mechanisms and sleep and mental health outcomes, and to obtain preliminary data needed as a prerequisite a larger-scale effectiveness trial. An emphasis is placed on studies that address the needs of youth from understudied and underserved populations.
The goals of this initiative are to examine mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS persistence in the setting of excellent virologic control using novel CNS cell systems, organoid models and single cell technologies
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this Notice of Funding Opportunity (NOFO) will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.
The purpose of this funding opportunity announcement (FOA) is to support developmental/exploratory studies in preparation for health promotion, disease prevention, treatment, or treatment services research to improve health in Native American (NA) populations. Applications may include 1) etiologic research, where there is a significant gap in knowledge, that will directly inform intervention development or adaptations, 2) research to develop and pilot test new or adapted interventions for feasibility, acceptability, and scalability, 3) research to test the short-term efficacy of interventions, 4) where a sufficient body of knowledge on intervention efficacy exists, research on strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions. Existing data suggest that significant acute and chronic disease inequities exist for NA populations. Concurrently, NA populations experience unique sociopolitical, historical, and environmental stressors and risks that may exacerbate health conditions and/or impact the effectiveness of existing solutions to address the conditions. They also possess unique strengths and resiliencies that can mitigate stressors or inform intervention strategies. Through this announcement, culturally informed exploratory/developmental research is sought that builds upon community knowledge, resources, and resilience to provide foundational knowledge for future science-based, culturally appropriate solutions to reduce morbidity and mortality through identification and remediation of precursors to diseases and disorders and through culturally informed treatment. For the purposes of this FOA, Native Americans include the following populations: Alaska Natives, American Indians (whose ancestral lands fall at least partially within the U.S. mainland border), and Native Hawaiians. The term Native Hawaiian means any individual any of whose ancestors were natives, prior to 1778, of the area which
The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
(Reissue of PAR-21-266) The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only SBIR Phase II and Fast-Track applications are supported under this program. SBIR Phase I applications are only accepted as part of a Fast-track application.
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease (AD) and its related dementias (ADRD) that need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this FOA.
The purpose of this NOFO is to support the Pediatric HIV/AIDS Cohort Study (PHACS) as a transformative and agile program addressingthe developmental and clinical course of persons living with HIV, and vertically acquired HIV, with an emphasis on youth through reproductive age.
The purpose of the Research and Entrepreneurial Development Immersion (REDI): NIA Entrepreneurship Enhancement Award (R25) is to promote the development of entrepreneurial training programs that are designed to broaden the skillset of graduate students and postdocs, as well as early career master's, Ph.D., and Dr.P.H. scientists, in fields relevant to the mission of NIA, including aging and Alzheimer's disease (AD) research. The goal of this program is to prepare trainees for a wide range of career paths, including those that are outside the normal research environment.
The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored researchers to tenure-track faculty conducting research that advances the mission of NIA. This three-year award provides protected time through salary and research support and is targeted at applicants who plan to start a tenure-track faculty position within a year of the award.
This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.
This BRAIN Initiative FOA is to further develop molecular tools of high impact that are targetable to brain cell types for the monitoring and manipulation of neural circuits in experimental animals. This FOA is part of the BRAIN Initiative Armamentarium for Brain Cell Access transformative project. This will support iterative improvement of molecular payloads capable of monitoring and manipulating neural cell activity and that can be delivered to specific brain cell types using targeting technologies.
The National Cancer Institute (NCI) Method to Extend Research in Time (MERIT) (R37) Award provides extended grant support to Early Stage Investigators (ESIs). By providing such an opportunity for longer term support to ESIs, the NCI intends to offer flexibility and opportunity for creativity and innovation and additional time to successfully launch their careers and to become more established before having to submit renewal applications (NOT-CA-18-037). The objective of the NCI's ESI MERIT Award is to allow eligible investigators the opportunity to obtain up to 7 years of support in two segments:
The NIAID New Innovator Award supports a postdoctoral and other candidates in non-independent positions or newly independent Early Stage Investigators of exceptional creativity who propose novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.
This Funding Opportunity Announcement (FOA) invites applications to use the NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of heart, lung, blood, and sleep (HLBS) disorders. The overall goal is to transition the program from genetic Map to Mechanism (M2) and to fill knowledge gaps that have not been sufficiently covered by existing TOPMed datasets. No funding will be provided under this FOA. The omics and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBIs BioData Catalyst (BDC).
This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
This Funding Opportunity Announcement (FOA) invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research.The National Institute on Aging (NIA) is pursuing this initiative to recruit early-stage investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a Program Director/Principal Investigator (PD/PI) at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain.
This Notice of Funding Opportunity (NOFO) is a single source application for one Coordination and Data Management Center (CDMC) to continue the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Clinical Centers are being solicited via RFA-DK-25-019 "Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CCs) (U01) Clinical trial optional)". The CDMC along with CCs will be expected to share results freely within Consortium and to continue the trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the Consortium members (see https://cpdpc.mdanderson.org/clinicalstudies.html).
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to enable the provision of support for AIDS Malignancy Consortium (AMC). AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas: Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical trials; Management of issues of international importance in HIV associated-malignancies; and Distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource (ACSR) for ongoing or future investigations. The AMC must consist of the following functional units: a Coordination Center; Clinical Trial Sites; Network Laboratories; and a Statistical Center. The AMC team must have scientific disease-oriented Working Groups to study Kaposi Sarcoma, Hematologic Malignancies , Human papilloma virus-associated cancers, and Solid Tumors in people with HIV. The Network Laboratories will be responsible for routine clinical trial support activities, pathogenesis-driven correlative studies, and clinical pharmacology and pharmacokinetics studies of anticancer/antiviral interactions. All clinical trials to be conducted by the AMC must be available to subjects of all racial/ethnic groups.
The Office of Research Infrastructure Programs (ORIP) within the Division of Program Coordination, Planning, and Strategic Initiatives announces an opportunity to apply for small grant support for ORIP-supported Special Emphasis Research Career Award (SERCA) K01 recipients who have completed the first two years (24 months) of the SERCA K01 award. ORIP seeks to enhance the ability of ORIP SERCA K01 awardees to conduct research as they transition to fully independent investigator status. The R03 mechanism supports projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support research projects that can realistically be completed in two years and that require limited levels of funding. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).
This Notice of Funding Opportunity (NOFO) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC). The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-25-018 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CDMC) (U01 Clinical Trial Optional)". To effectively contribute to the ongoing CPDPC clinical studies, each CC applicant should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the CPDPC (see https://cpdpc.mdanderson.org/clinicalstudies.html). Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.
The purpose of this Notice of Funding Opportunity (NOFO) is to develop multi-organ automated microphysiological systems (MPS) for studying the effects of microgravity conditions on human body in low Earth orbit at the International Space Station National Laboratory (ISS-NL). This program will provide insights on human patho(physiology), especially aging-related functional decline and age-related diseases. The multi-organ MPS configuration will allow better modeling of the whole organism. Improved automation with extended longevity of MPS will facilitate longer experiments in space and the collection of more physiologically relevant data. The inclusion of samples representing the broad spectrum of diversity in the human population will allow for better modeling of aging progression and development of interventions.
This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific workforce, and research portfolio. The purpose of this initiative is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial/ethnic populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged.
The goal of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition to assist awardees in launching competitive, independent research careers.
The purpose of this reissued Funding Opportunity Announcement (FOA) is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high-risk, high-impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated Go/No-Go criteria by the end of Year 2.
(Reissue of RFA-NS-16-021, PAR-18-413, RFA-NS-19-039) Diffuse brain white matter disease is highly prevalent in the elderly, and has been clinically associated with vascular contributions to cognitive impairment and dementia (VCID) in both men and women. Diffuse white matter disease is thought to include a variety of pathologies including demyelination and/or fiber loss due to multifocal infarction and local ischemia. It is often accompanied by arteriosclerosis in deep penetrating arteries, multiple infarcts in the basal ganglia, brainstem or cerebellum. Though most commonly extending out from the periventricular surfaces, it may also occur in subcortical white matter. Diffuse white matter disease is typically detected in clinical settings as hyperintensity on magnetic resonance imaging (MRI) or signal loss on computed tomography x-ray (CT) scan; diffuse white matter disease can be detected histologically as well, for example in human pathology and in studies using animal models. Despite the prevalence and potential significance of white matter disease for cerebrovascular disease etiology and cognitive outcomes, much remains to be learned about the cellular and molecular causes, regional vulnerability, and progression over time. The physiological consequences of diffuse white matter disease on local axon and neural circuit function are almost completely unknown. The purpose of this FOA is to address some of the many gaps in knowledge of the biologic mechanisms of the commonly occurring, cerebrovascular disease and age-related diffuse white matter disease at the molecular, cellular, tissue and brain circuit level. The ultimate goal of this fundamental research is to inform future efforts to reduce the burden of illness due to age-related vascular contributions to cognitive impairment and dementia.
Through this Notice of Funding Opportunity Announcement (NOFO), the National Cancer Institute (NCI) intends to expand the research scope and leverage the gains made through the NOFO entitled Investigation of the Transmission of KSHV (RFA-CA-18-013 and RFA-CA-20-046) to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such as multicentric Castleman disease (MCD), primary effusion lymphoma (PEL) and KSHV inflammatory cytokine syndrome (KICS) or ameliorate the severity of disease. A therapeutic KSHV vaccine could be helpful in preventing or treating KSHV disease in people who are already infected with KSHV. Research areas could include, but are not limited to: (1) Identification and evaluation of KSHV structural and non-structural targets for a potential KSHV vaccine; (2) Development of animal models to study a prototype KSHV vaccine or vaccines; (3) Development and testing of a candidate KSHV vaccine or vaccines; (4) Studies to assess how the efficacy of a promising KSHV vaccine can be optimized for PWH; (5) Research to better define the initial steps of infection with KSHV and the primary means of person-to-person transmission in different populations that can be targeted with a vaccine; and (6) Optimization and/or standardization of KSHV detection methods.
The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).
The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies.
This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
The purpose of this initiative is to advance the science and implementation of innovative multi-level health care research for older adults from populations that experience health disparities. The initiative will support research designed to (1) gain a better understanding of appropriate screening, diagnostic, and clinical care guidelines in a primary care setting, (2) explore shared decision-making that is needed to enhance care planning and patient agency between clinicians and care teams with the older adult and their caregiver(s), and (3) identify effective strategies for care coordination.
The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the TrialNet Coordinating Center (TNCC). The TrialNet network identifies people with type 1 diabetes (T1D) at stages before and after onset of clinical symptoms and enrolls them in trials and studies aimed at prevention of progression to clinical disease and preservation of insulin production. The TNCC participates in ongoing studies and intervention trials as well as the design and conduct of new studies and intervention trials. The TNCC will: (1) support a wide range of research projects in varying stages of development, implementation and completion, and (2) provide data and sample management, including standardized acquisition, quality control, dissemination and public accessibility. The TNCC will be responsible for network administration and operations, including the evaluation, selection, and funding (through subcontracts) of Clinical Centers and central support units (such as laboratories) necessary for the conduct of TrialNets clinical studies. The TNCC PD/PI will be a voting member of the TrialNet Executive and Steering Committees, contributing to network leadership. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
This NOFO would support development and validation of novel clinically- and/or pathophysiologically-relevant human cellular models of ADRD. The cellular model systems would be expected to capture the multi-faceted pathologies and multiple cell types observed in ADRDs. Validation includes internal, face, construct, and predictive (to the extent possible) validation. These models can be developed/validated with the goal of supporting therapy development or better understanding of human disease mechanisms and mechanisms that uncover predisposition to developing neurodegenerative dementias. Human cellular models need to be novel, complex, and address a gap in the currently available models. Multidisciplinary teams will be highly encouraged. Leveraging the use of and depositing new cells into existing NIH cell repository resources will also be encouraged.
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. To be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.
The purpose of this notice of funding opportunity (NOFO) is to support studies to delineate the mechanisms by which sex hormones influence the consequences of comorbid HIV and drug use and use this knowledge to explore biological mechanisms as potential therapeutic targets to address HIV-substance use disorders (SUD) comorbidity. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
This NOFO solicits applications that stimulate innovation and advance understanding of when, where and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons irrespective of racial/ethnic background or socioeconomic status. The R03 grant mechanism supports small research projects that can be carried out in a short period of time with limited resources, such as pilot or feasibility studies; secondary analysis of existing data; small, self-contained research projects; or development of research methodology. An R03 grant application need not have extensive background material or preliminary information. Accordingly, reviewers will emphasize the conceptual framework, the level of innovation, and the potential to significantly advance our knowledge or understanding. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or, when available, from investigator-generated data. Preliminary data are not required for R03 applications; however, they may be included if available.
This Funding Opportunity Announcement (FOA) invites grant applications aimed at elucidating neuroimmune and neuronal-glial pathophysiological mechanisms of HIV-associated neurological disorders (HAND) using ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the presence of addictive substances. Specific emphasis is on unbiased, reproducible analysis of genetics and epigenetics, neuroglial interactions, and neuroimmune cell activities from the single cell to neural circuit levels.
The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the l?e?a?d?i?n?g? ?e?d?g?e? of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.
(Reissue of PAR-18-665) This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support clinical trials for projects that were previously funded by NIH SBIR and STTR Phase II awards. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of SBIR Phase II projects to the commercialization stage by promoting partnerships between NIH's SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.
This Notice of Funding Opportunity (NOFO) invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity.NORCs support three primary research-related activities:Research Core services, a Pilot and Feasibility (P and F) program, and an Enrichment program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in nutrition and obesity.
The purpose of this notice of funding opportunity (NOFO) is to support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) or Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening) to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses.
This funding announcement solicits R21 grant applications that propose exploratory/developmental research projects that are consistent with the research framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.
Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.
The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) pre-trial feasibility and acceptability testing of services and service system research relevant to the prevention of substance use. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through FOA include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.
The purpose of this notice of funding opportunity (NOFO) is to support research projects that aim to further understanding of the developmental trajectories of late talking children by leveraging existing data and creating open and shared data resources to aid in identifying patterns and predictors of developmental outcomes in late talking children, and exploring potential underlying mechanisms, risk factors, and sequalae.
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes. The goal of this NOFO is to support proof of concept studies for feasibility and exploratory development. Feasibility must not have already been developed in the literature or with preliminary data. While unpublished data are not permitted, references and data from widely available preprints that have a Digital Object Identifier (DOI) are acceptable. Investigators who have generated unpublished preliminary data should submit a proposal to companion R01.
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a specified target measure. If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on target engagement(s) when used by humans and assess whether there is an association between the degree of the impact on the target engagement and clinical outcomes in a participant population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same target engagement measure; or study the impact of the natural product in a population that is more responsive,
This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.
This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and stimulant use disorders (StUD). Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics; and (2) medical therapeutic and diagnostic devices, including software as a medical device. This FOA strives to contribute to the effort against national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis.
The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal the PAIRS program is to the development of radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.
This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA.
The purpose of this Notice of Funding Opportunity (NOFO) is to reissue PAR-24-256 "Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Aging (R34 Clinical Trial Required)" in order to support proof-of-concept feasibility trials guided by the NIH Music-based Interventions (MBI) Toolkit for research on brain disorders of aging. These early stage clinical trials will generate evidence supporting the validity of the NIH MBI Toolkits guiding principles as well as the necessary pilot data to assess the feasibility of the design for a subsequent clinical efficacy or effectiveness study (or pragmatic clinical trial) using music-based interventions in the context of brain disorders of aging, including but not limited to Alzheimers disease and Alzheimers disease-related dementias, Parkinsons disease, and stroke. The data collected should address gaps in scientific knowledge in order to facilitate development of a competitive large-scale clinical trial.
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.
The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions
Reissue of RFA-NS-18-020: Understanding the dynamic activity of brain circuits is central to the NIH BRAIN Initiative. This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). This FOA seeks exceptionally creative approaches to address major challenges associated with recording and modulating CNS activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain. It is expected that the proposed research may be high-risk, but if successful, could profoundly change the course of neuroscience research. Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, magnetic, acoustic and/or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.
Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.
The objective of this Notice of Funding Opportunity (NOFO) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development, and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety, and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.
This R01 funding opportunity encourages projects that test, in animals and/or humans, whether modifying electrophysiological patterns can improve cognitive, affective, or social processing. This R01 FOA is expected to have a companion R21 version. The proximal goal of this FOA (and its companion R21 version) is to encourage investigators to test whether modifying specific patterns of coordinated neural activity in vivo can improve cognitive, social, or affective processes. These studies should be based on a rational understanding of the role of specific neural activity rhythms in, for example, the routing of information among brain regions or in improving the ability of afferent information to affect local processing via coherence of underlying oscillatory activity.